Viking Therapeutics shares are trading higher. Roth MKM assumed coverage on the stock with a Buy rating and $32 price target.
Portfolio Pulse from Bill Haddad
Viking Therapeutics shares are trading higher after Roth MKM assumed coverage on the stock with a Buy rating and a $32 price target.
May 31, 2023 | 6:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics shares are up following Roth MKM's Buy rating and $32 price target.
Viking Therapeutics (VKTX) shares are trading higher due to the positive Buy rating and $32 price target from Roth MKM. This indicates a bullish outlook for the stock, which is likely to attract more investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100